Assessment of the Hemophagocytic Lymphohistiocytosis HScore in Patients With Coronavirus Disease 2019
Kristina E N Clark, William D Nevin, Tabitha Mahungu, Helen J. Lachmann, Animesh Singh
Abstract
The clinical manifestation of moderate to severe coronavirus disease 2019 (COVID-19) has parallels to secondary hemophagocytic lymphohistiocytosis (HLH) both clinically and based on molecular inflammatory response. We found no evidence to support the utility of risk-stratifying COVID-19 patients using risk scoring methodology designed for HLH.
Topics & Concepts
Hemophagocytic lymphohistiocytosisMedicineCoronavirus disease 2019 (COVID-19)DiseasePandemicParallelsSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakCoronavirusImmunologyPediatricsVirologyInfectious disease (medical specialty)Internal medicineOutbreakMechanical engineeringEngineeringAutoimmune and Inflammatory Disorders ResearchImmune Cell Function and InteractionKawasaki Disease and Coronary Complications